Saint-laurent, Canada
IntelGenx Corp., headquartered in Canada, positions itself as a leader in pharmaceutical films, leveraging cutting-edge film technologies like VersaFilm®, VetaFilm™, and transdermal solutions. Founded in 2003, the company specializes in developing and manufacturing innovative drug delivery systems that cater to unmet medical needs across various therapeutic conditions.
Their offerings are distinctive due to the significant benefits they provide both patients and physicians, addressing critical challenges within the Biotechnology, Health Care, and Pharmaceutical industries. IntelGenx also prides itself on its extensive pharmaceutical services, including R&D, analytics, clinical monitoring, and regulatory compliance. Their state-of-the-art facilities support a full production scale, from lab to commercial.
Backing their potential, ATAI Life Sciences participated in a recent $3.00M post-IPO equity investment on 31 August 2023, signaling strong market confidence in their technologies and strategic direction.
